Ozempic, Zepbound and food and drug administration
Drug makers can’t make knockoff weight-loss drugs anymore—and they’re mad
With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to the drug makers, writing in bold that the agency "reminds compounders of the legal restrictions on making copies of FDA-approved drugs."
Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.
Healgen Scientific's combined COVID-19 and flu test gives people a new way to check what's causing their symptoms, FDA says.
According to the FDA announcement, the recall includes approximately 9,986,245 pounds of ready-to-eat meat and poultry ...
The U.S. Food and Drug Administration on Thursday announced it has authorized the use of the Healgen Rapid Check COVID-19/Flu ...
Bimbo Bakeries USA, which includes brands such as Sara Lee, Entenmann's and Ball Park buns and rolls, appears to be defying ...
AI-based clinical simulation systems can be a game-changer for the pharmaceutical industry. The ability to predict clinical ...
Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...
The FDA's Tala Fakhouri discusses the agency's approach to the regulation of AI in clinical trials in a new interview.
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in ...
Careers in food science not only focus on improving food quality but also on addressing challenges like food security, waste ...
Issue: Whether a manufacturer may file a petition for review in a circuit (other than the U.S. Court of Appeals for the District of Columbia Circuit) where it neither resides nor has its principal ...
On October 2, 2024, the U.S. Food and Drug Administration (FDA) determined the shortage of the tirzepatide injection, a glucagon-like peptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback